NCT07222982 Social Groups for Autistic Young Adults (SDARIYA)
| NCT ID | NCT07222982 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Drexel University |
| Condition | Autism Spectrum Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 54 participants |
| Start Date | 2026-01-15 |
| Primary Completion | 2030-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 54 participants in total. It began in 2026-01-15 with a primary completion date of 2030-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a clinical trial that will test whether a group program called SDARI (Socio-dramatic Affective Relational Intervention) can help autistic young adults between the ages of 18 and 30 feel more connected to others and improve their social relationships. The study will try to answer: Can SDARI be used successfully with autistic adults? Does SDARI help people feel more connected, supported, and mentally well? There are two groups in the study. One group will participate in the SDARI program, and the other group will do different structured activities that don't focus on social connection. Researchers will compare the two groups to see if SDARI leads to better outcomes. Participants will: Complete screening to confirm eligibility (including autism traits and IQ) Attend weekly in-person group sessions for 10 weeks Take part in games and activities designed to support connection and collaboration Complete surveys and interviews before, during, and after the program Have the option to choose someone close to them (like a friend or family member) to fill out surveys about their experiences
Eligibility Criteria
Inclusion Criteria: * Have graduated from high school (or an equivalent program) and are between the ages of 18-30 years old * Demonstrate the ability to complete consent and all study measures and procedures in English * Score ≥ 65 on the RAADS * Score ≥ 70 on the KBIT-2R * Score ≥ 6 on the ADOS-2 Module 4 * Are physically able to complete study activities (e.g., no significant physical impairment or mental condition restricting participation in study activities). * Are physically able to travel to the AJ Drexel Autism Institute at Drexel University in Philadelphia, PA to attend all weekly study sessions Exclusion Criteria: * Are still enrolled in high school (or an equivalent program) or are not between the ages of 18-30 years old * Are unable to complete study measures and/or procedures in English * Are unable to complete consent procedures * Score ≤ 65 on the RAADS * Score ≤ 70 on the KBIT-2R * Score ≤ 6 on the ADOS-2 * Cannot physically complete study activities * Cannot physically travel to the AJ Drexel Autism Institute at Drexel University in Philadelphia, PA to attend study sessions * Have a severe medical or psychiatric condition preventing them from safely completing study activities
Contact & Investigator
Matthew Lerner, PhD
PRINCIPAL INVESTIGATOR
Drexel University
Frequently Asked Questions
Who can join the NCT07222982 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 30 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07222982 currently recruiting?
Yes, NCT07222982 is actively recruiting participants. Contact the research team at china.parenteau@gmail.com for enrollment information.
Where is the NCT07222982 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07222982 clinical trial?
NCT07222982 is sponsored by Drexel University. The principal investigator is Matthew Lerner, PhD at Drexel University. The trial plans to enroll 54 participants.